First National Bank of Omaha Makes New Investment in United Therapeutics Corporation $UTHR

First National Bank of Omaha purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,198 shares of the biotechnology company’s stock, valued at approximately $2,816,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Leuthold Group LLC increased its holdings in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG boosted its holdings in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after acquiring an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP boosted its holdings in United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after acquiring an additional 3,766 shares during the last quarter. M&T Bank Corp grew its position in United Therapeutics by 171.6% during the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock valued at $1,531,000 after acquiring an additional 1,985 shares during the period. Finally, Seven Fleet Capital Management LP purchased a new stake in United Therapeutics during the fourth quarter valued at about $633,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,356,182.60. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $506.59, for a total transaction of $4,812,605.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $164,359,579.37. The trade was a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 452,575 shares of company stock valued at $245,684,184. 8.60% of the stock is owned by insiders.

United Therapeutics Price Performance

Shares of UTHR stock opened at $518.27 on Wednesday. The company’s fifty day moving average price is $534.53 and its two-hundred day moving average price is $536.74. The firm has a market capitalization of $22.23 billion, a P/E ratio of 18.54, a P/E/G ratio of 1.69 and a beta of 0.59. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the previous year, the company earned $6.41 earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.